

This script OK'd by ADB 3/4/19

Identification and characterisation of anti - *Pseudomonas aeruginosa* proteins in mucus of
the brown garden snail, *Cornu aspersum*

SJ Pitt ^{a*}, JA Hawthorne ^a, M Garcia-Maya ^b, A Alexandrovich ^b, RC Symonds ^c A Gunn ^c

a. School of Pharmacy and Biomolecular Sciences, University of Brighton, Lewes Road,
Brighton BN2 4GJ, UK

b. Randall Division of Cell and Molecular Biophysics, King's College London, Guy's Campus,
London SE1 1UL

c. School of Natural Sciences and Psychology, Liverpool John Moores University, Byrom
Street, Liverpool L3 3AF, UK

* corresponding author ORCID ID: 0000-0002-9215-6517

School of Pharmacy and Biomolecular Sciences, University of Brighton, Lewes Road,
Brighton BN2 4GJ, UK

s.j.pitt@brighton.ac.uk

Tel: 01273 - 642047

ABSTRACT

Background

Novel antimicrobial treatments are urgently needed. Previous work has shown that the mucus of the brown garden snail (*Cornu aspersum*) has antimicrobial properties, in particular against type culture collection strains of *Pseudomonas aeruginosa*. We hypothesised that it would also be effective against clinical isolates of the bacterium and that investigation of fractions of the mucus would identify one or more proteins with anti-pseudomonal properties, which could be further characterised.

Materials and methods: Mucus was extracted from snails collected from the wild. Antimicrobial activity against laboratory and clinical isolates of *Ps. aeruginosa* was determined in disc diffusion assays. Mucus was purified using size exclusion chromatography and fractions containing anti-pseudomonal activity identified. Mass spectroscopy and high performance liquid chromatography analysis of these fractions yielded partial peptide sequences. These were used to interrogate an RNA transcriptome generated from whole snails.

Results: Mucus from *C. aspersum* inhibited growth of type collection strains and clinical isolates of *Ps. aeruginosa*. Four novel *C. aspersum* proteins were identified; at least three are likely to have antimicrobial properties. The most interesting is a 37.4 kDa protein whilst smaller proteins, one 17.5 kDa and one 18.6 kDa also appear to have activity against *Ps. aeruginosa*.

Conclusions: The study has identified novel proteins with antimicrobial properties which could be used to develop treatments for use in human medicine.

Key words: antimicrobial; transcriptome; lectin; mucus; *Cornu aspersum*, *Pseudomonas aeruginosa*, transcriptome

Introduction

1
2
3 Antimicrobial resistance is a major public health problem [1] and scientists and clinicians
4
5 need to devise protocols that encourage more efficient and sparing use of antimicrobial
6
7 agents [2, 3] in order to limit this. Multidrug resistant strains of many important pathogens,
8
9 including *Pseudomonas aeruginosa* have emerged [4]. Thus, there is a requirement to
10
11 develop new antimicrobial agents. One approach is to investigate mechanisms of resistance
12
13 and thereby design drugs that can overcome them [5]. Another is to explore the reliability of
14
15 accounts of the effectiveness of natural remedies. This has yielded some significant
16
17 outcomes including the development of artemisinin to treat chloroquine-resistant strains of
18
19 the malaria parasite *Plasmodium* spp. [6] and tea tree oil for skin infections [7].
20
21
22
23
24
25
26

27
28 *Ps. aeruginosa* is an opportunistic pathogen in humans; it is associated with a range of
29
30 clinical presentations, including lower respiratory tract infections, septicaemia, wound
31
32 infections and ear infections [8]. Nosocomial acquisition is a risk, especially in
33
34 immunocompromised patients and those with severe burns [9]. Patients with cystic fibrosis
35
36 are especially susceptible to respiratory infections with *Ps. aeruginosa*. Infection can be
37
38 intractable, since the bacteria form biofilms within the lungs which antibiotics cannot fully
39
40 penetrate [10]. Multidrug resistant and extreme multidrug resistant strains of *Ps.*
41
42 *aeruginosa* are of increasing concern [8, 10]. The bacterium is ubiquitous in the
43
44 environment and pseudomonal infections are found in vertebrates, invertebrates and plants
45
46 [11, 12]. Therefore, the strategies different organisms employ for defence against *Ps.*
47
48 *aeruginosa* might be a source of naturally occurring antimicrobial agents, which could be
49
50 used in human medicine.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The common brown garden snail, *Cornu aspersum* (*Helix aspersa*) has been valued for its
2 healing properties since ancient times [13]. Snail-based remedies have been advocated for
3 the treatment gastrointestinal and respiratory conditions, infections characterised by rashes
4 (including measles and smallpox), hernias and skin lesions [13]. Terrestrial molluscs secrete
5 mucus, which is a viscous and biochemically complex substance. It facilitates locomotion,
6 helps reduce water loss, acts as a defence against predators and its components enable
7 communication between snails of the same species [14]. Among the constituents of snail
8 mucus are glycoproteins, some of which are lectins with agglutination properties [15].
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Cosmetic preparations containing extracts of *C. aspersum* mucus are currently widely marketed for the reduction of wrinkles and scarring [16, 17]. However, mucus extracts also promote healing of burn wounds [18] and preliminary work indicates that they have anti-tumour properties and might have promise for treating melanogenesis [19]. To date, there have been few studies on the antimicrobial properties of the mucus of terrestrial molluscs [20] and most workers have focussed on the African Giant Land snail, *Achatina fulica*. Its mucus contains a 160 kDa glycoprotein 'achacin', which displays fairly broad-spectrum antimicrobial properties [20, 21, 22, 23] and a 9 kDa antimicrobial peptide [24]. *C. aspersum* mucus also has antimicrobial activity, attributable to one or more proteins between 30 and 100 kDa in size [25, 26]. There are two candidate proteins in this range – one approximately 50 kDa [25, 26] and the other estimated as between 30 and 40 kDa [25] or 41 kDa [26].

In previous studies, preparations of *C. aspersum* mucus exhibited very clear activity against several laboratory-adapted culture collection strains of *Ps. aeruginosa* [26]. To investigate whether *C. aspersum* contains any antimicrobial agents which would be clinically useful, tests against isolates from patients are required. Testing of *Ps. aeruginosa* strains obtained

1 from patients with cystic fibrosis would be the logical place to start this work. In addition,
2 development of any such product requires identification and characterisation of the protein
3 (s) responsible for the observed effects.
4
5
6

7
8 Therefore, the hypothesis for this present study was: *C.aspersum* mucus contains one or
9 more proteins that have antimicrobial activity against *Ps.aeruginosa*
10
11
12
13
14
15
16
17

18 **Materials and methods**

19
20
21 Twenty *Cornu aspersum* snails were collected from the wild in East Sussex, UK . They were
22 placed in clear plastic tanks, part-filled with moist coconut husk substrate. These were kept
23 in a room with ambient light and average temperature of 20 °C. The snails were fed
24 cucumber, butternut squash, green peppers, lettuce, and carrots and a provided with a
25 source of calcium.
26
27
28
29
30
31
32

33
34 Mucus was collected by stimulating the snails with a cotton swab moistened in phosphate
35 buffered saline (PBS) as described previously [25]. Mucus was harvested using a 5mL plastic
36 Pasteur pipette and, after settling at room temperature for 1-2 hours, placed into a 20mL
37 sterile plastic bijoux bottle and diluted approximately 1:2 with PBS. The preparation method
38 was modified to include an additional step of placing 2-4 8mm glass beads into the bijoux
39 before shaking overnight (18-20 hours) at 4 °C. The shaken mucus was centrifuged at 4000
40 rpm for 20 minutes to sediment large debris. The resulting supernatant was passed through
41 a 0.45 micron filter after which its protein content was determined using a Nanodrop 2000
42 spectrophotometer (Thermo Scientific, East Grinstead, West Sussex, UK) and found to be
43 between 4.0 and 8.0mg/ mL (n=4).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

As required, size separation was carried out in Vivaspin 500 columns (Sartorius Stedim Lab Ltd, Stonehouse, Gloucestershire, UK) at 1,000 kDa , 100 kDa, 30 kDa. The filtrate from the 1,000 kDa column was used to eliminate larger proteins. The 100 kDa and 30 kDa separation columns were used to concentrate the mucus fraction containing proteins between those two sizes, since previous work [25] had identified the active ingredient in *C. aspersum* to be in that size band.

Antimicrobial testing was as follows. Mucus was tested for anti-microbial activity against *Ps. aeruginosa* NCIMB 10548, *Ps. aeruginosa* NCTC 10662 and five well characterised clinical isolates of *Ps. aeruginosa* . These were isolates 2, 9, 10, 34 and 43 from the panel compiled by De Soyza *et al.* [27], which all originated from patients with cystic fibrosis. Disc diffusion assays were undertaken as previously described [26] using overnight Tryptone Soy Broth (Oxoid, Basingstoke, Hampshire, UK) cultures, diluted in PBS to between 10^6 and 10^7 colony forming units (cfu) per mL (verified by viable count). Aliquots of 100 μ L were placed onto Isosensitest agar (ISA; Oxoid) plates and left to dry for 15 minutes. Then between three and six 5mm sterile assay discs were placed on the plates and 50 μ L of prepared mucus added to each disc. Every plate set up included a PBS control disc. Plates were left to dry for a further 40-60 minutes before incubation overnight (18-20 hours), aerobically at 37 °C. Zones of inhibition were recorded in mm. A minimum of three replicates was tested against a particular strain of bacterium, but in most cases it was more than six.

For Size Exclusion Chromatography (SEC), prepared *C. aspersum* mucus was loaded on to a Superdex 75 16/60 column (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire,

1 UK), previously equilibrated with PBS. The column was run at 1 mL/min and fractions of 1.5
2 mL were collected. These fractions were submitted to SDS-PAGE and those showing the
3 same protein pattern were pooled, concentrated using a 5 kDa cut -off Millipore spin filter
4 and analysed by SDS-PAGE. Two proteins which appeared to be present in high
5 concentrations were cut out from the gel and sent for analysis by Mass Spectroscopy.
6
7

8 This experiment was repeated using a Superdex 75 26/60 column (GE Healthcare Life
9 Scientific), with the column run at 2 ml/min and fractions of 2 ml. The elution profile,
10 monitored at 280nm showed several peaks. Eluted fractions were bulked into pools
11 (labelled 1-6), based on protein pattern. Five of the resulting pools (2 to 6) were tested in
12 duplicate against *Ps. aeruginosa* NCIMB 10548 in the disc diffusion assay described above
13 and they were also examined by SDS-PAGE. One of the proteins observed was excised from
14 the gel and analysed further by HPLC – chromatogram sequencing.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Proteins selected for further analysis by mass spectrometry were separated using SDS-PAGE
32 taking account of precautions to minimise keratin contamination. The resulting gel was sent
33 to the Centre of Excellence for Mass Spectrometry, King's College London. Two proteins
34 from the SDS-PAGE were selected for MS analysis, one of approximately 50 kDa and the
35 other estimated to be between 17 and 18 kDa in size. Selected proteins were excised from
36 the gel and de-stained then reduced (with dithiothreitol {DTT}), treated with iodoacetamide
37 (to alkylate any free cysteine residues) and digested overnight with trypsin. The resulting
38 peptide fragments were washed and then lyophilised after which they were re-suspended in
39 50mM ammonium bicarbonate. The suspensions were then subjected to reverse phase
40 chromatography in an EASY NanoLC (Thermo Scientific) Ultra HPLC analyser and the eluted
41 peptides ionised by electrospray and fragmented in an Orbitrap Velos Pro using collision-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 induced dissociation. The 20 ions that registered most strongly were analysed in the
2 Proteome Discover V1.4 software and compared to peptide sequences in the Uniprot
3 database. The data were also analysed with the PEAKS mass spectrometry software.
4
5 Resulting peptides were compared with sequences in a *Helix pomatia* database (New
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
England Biolabs, MA, USA).

For HPLC-chromatogram sequencing, prepared mucus was concentrated by passing it
through 1MDa and 100 kDa Vivaspin 500 columns (Sartorius) and running out in an SDS-
PAGE gel. The fraction of interest (30-40 kDa) was cut and sent to The Proteome Factory AG,
Berlin, Germany, where sequencing analysis was undertaken by Ms Julia Schendel. Using
HPLC–chromatogram analysis a series of peptides was obtained after digestion with trypsin,
chymotrypsin, elastase and LysC.

For RNA transcriptome sequencing, individual *C. aspersum* snails were stimulated to
produce mucus as described above and then snap frozen in liquid nitrogen. After freezing,
the shell was broken off and the body ground to a paste in a pestle and mortar; the pestle
and mortar were kept cold throughout this process. Total RNA was extracted using the
E.Z.N.A.(r) Mollusc RNA Kit (Omega BIO-TEK, Norcross, USA.), following the manufacturer's
instructions for the long protocol. Total RNA was quantified for purity and integrity by UV-
Vis spectroscopy (NanoDrop, ThermoScientific, Waltham, Massachusetts, USA. Samples
were then stored at -80°C before transport to The University of Liverpool, Centre for
Genomic Research. RNA was further purified using an RNA Clean & Concentrator kit (Zymo
Research, California, USA) and total RNA quantified using a 2100 Agilent Bioanalyzer (RNA
Nanochip, Agilent Technologies, Waldbronn, Germany).

1 The sample was treated with a Teloprime full length cDNA amplification kit (Lexogen GmbH,
2 Vienna, Austria) following the manufacturer's protocol. The product was checked for
3 concentration and profile using a bioanalyser high sensitivity chip.
4
5

6
7 The ends of the sample were damage and end repaired using the Template preparation kit
8 (Pacific Biosciences, California, USA). After cleaning with Ampure XP beads (Beckman
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The SMRTbell library was treated with exonuclease to remove non circular DNA. The SMRTbell library was cleaned and this was used to load sequel cells using diffusion loading at 6pM on plate concentration and a 2 hour pre extension.

The resulting PacBio READS where analysed at the University of Liverpool, Centre for Genomic Research using the ISO-seq pipeline (SMRT link software 5.0.1.9585) with the default parameter settings. The transcriptome was annotated using TransDecoder (version 3.0.1) for each strand and protein sequences were annotated using BLASTp_(National Center for Biotechnology Information [NCBI], Bethesda, MD;<http://www.ncbi.nlm.nih.gov/BLAST/>). Protein sequences with a blast e-val below 0.01 were selected as best match.

The transcriptome was probed using the peptide sequences obtained from Mass Spectroscopy and HPLC using BLASTn. Matches to transcripts were further analysed using the EXPASY translate tool (<https://web.expasy.org/translate/>) to search for open reading frames. Proteins found to match to the relevant peptides were subjected to analysis using BLASTp.

Results

1
2 For antimicrobial spectrum of activity in *C. aspersum* mucus, zones of inhibition were
3
4 observed in all cases when the mucus was tested against the laboratory strains and clinical
5
6 isolates of *Ps. aeruginosa*. Figure 1 is an example of an anti-microbial disc diffusion assay
7
8 plate where mucus was tested against *Ps.aeruginosa* NCIMB 10548. It shows a very narrow
9
10 zone of clearing (<0.1mm) around the PBS control and obvious zones of inhibition around
11
12 the three control discs. The mean zones of inhibition recorded for the culture collection and
13
14 clinical isolates of *Ps.aeruginosa* were all between 9 and 13mm.
15
16
17
18
19
20
21
22

23 Size exclusion chromatography of *C. aspersum* mucus proteins was as follows. During the
24
25 first Superdex column run, two peaks were eluted. Although one of these peaks appeared to
26
27 represent three distinct protein fractions, they all showed similar protein patterns on SDS-
28
29 PAGE. One of these fractions (A) is shown in Figure 2a, along with the proteins from the
30
31 second peak (B). There were strongly staining bands at approximately 50 kDa and 17 kDa
32
33 and these two bands were sent for Mass Spectroscopy.
34
35
36
37
38
39
40

41 Figure 2b shows the trace obtained from the second SEC procedure; the peaks are labelled 1
42
43 to 6, where 1 contains the protein aggregates. Figure 2c is the SDS-PAGE gel carried out on
44
45 the fractions on the day of the SEC experiments, indicating the proteins detected in each
46
47 fraction. Table 1 shows the estimated sizes of the proteins detected in each fraction and
48
49 which ones were found to have antibacterial activity.
50
51
52
53
54
55
56

57 Peptides identified in *C. aspersum* mucus from mass spectrometry analysis and HPLC-
58
59 chromatographic analysis were as follows. From the first SEC experiment the ~17 kDa and
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

the ~50 kDa proteins (indicated in Figure 2a) were selected for Mass Spectrometry analysis.

Table 2 shows the putative peptides obtained after deduction in comparison with a *H. pomatia* database. After the antimicrobial analysis of the fractions from the second SEC (Table 2), the protein of approximately 39 kDa was sent for the HPLC-chromatographic analysis; the peptides obtained from this are also shown in Table 2. Using these peptides to probe the transcriptome database, four proteins were identified, as indicated in Table 2.

Transcriptome sequencing and assembly were as follows. Using the peptide sequences (Table 2) to probe the proteins identified in the RNA transcriptome revealed that peptide 1 aligned to a single match in the transcriptome. This sequence had 4 open reading frames, the longest of which is a protein sequence of 159 amino acids (17.5 kDa) (protein 1), (Figure 3). Protein 1 contains a conserved region of the complement Cq1 superfamily. Protein 1 has been submitted to the NCBI GenBank and allocated the accession number MK393387.

A combination of peptides 3,5 and 6 matched to a 583 amino acid protein (64 kDa) that was identified as protein 2 (Figure 3).

Peptide 11 matched to a 169 amino acid protein (18.6 kDa) (Figure 3) that was identified as protein 3. Amino acids 1- 155 map to a conserved region in the fibrinogen related domain (FReD) superfamily. Protein 3 has been submitted to the NCBI GenBank and allocated the accession number MK393388.

A combination of peptides 12, 13, 14, 15,16, 17 and 18 matched to a protein of 340 amino acids in length (37.4 kDa), labelled protein 4 (Figure 3). This sequence appeared in three separate places in the transcriptome. Two of these sequences have been submitted to the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

NBCI GenBank and allocated the accession numbers MK393385 and MK393386. Amino acids 150 to 340 map to a conserved region from the von Willebrand Factor A superfamily.

Discussion

This study has confirmed the findings of Pitt *et al.* [25] and Bortolotti *et al.* [26] that *C. aspersum* mucus contains one or more proteins with anti-microbial activity against *Ps. aeruginosa*. The results for the antimicrobial plate assay were essentially qualitative, since the concentration of the active ingredient(s) within the mucus was not known.

Nevertheless, clear and reproducible zones of inhibition were obtained not only with the type culture collection strains, but with all five clinical isolates which came from patients with cystic fibrosis.

This is an important finding as it indicates that further characterisation of the active ingredient(s) is justified. Previous work on *C. aspersum* mucus identified two possible proteins in the size range of between 30 kDa and 100 kDa on SDS-PAGE with anti-microbial activity against *Ps. aeruginosa* [25, 26] and this was confirmed by repeated plate assays (S. Pitt, unpublished data) and Minimum Inhibitory Concentration experiments (J. Hawthorne, unpublished data). One of the proteins is between 50 and 60 kDa and the other between 30 and 40 kDa. Analysis by SDS-PAGE of the fractions of mucus obtained by the SEC procedure revealed proteins that corresponded with these sizes (Figures 2a and 2c). In addition, the SDS-PAGE of the unfractionated mucus showed clear bands in the 10-20 kDa size regions (Figures 2a and 2b). Some or all of these are likely to be lectins, which are common components of gastropod mucus. There are various classes of lectins and some of them function in the invertebrate immune response [28, 29]. Lectins also play a role in mollusc mucus function, including binding /attaching to substrates and contributing to viscosity.

1 They have also been found to have unexpected properties with respect to binding
2 mammalian cells. For example, *C. aspersum* mucus extracts promote wound healing by
3 stimulating the proliferation and migration of mammalian fibroblasts [30]. Similarly, the
4 ability of the *H. pomatia* agglutinin (HPA) to attach to mammalian cells expressing the N-
5 acetylgalactosamine surface protein, which is a marker of malignancy. A 12 kDa lectin with
6 similar properties is present within *C. aspersum* mucus. It binds to very specific mammalian
7 cell surface markers and has been extensively characterised with a view to using it in
8 diagnostic assays for cancers and other conditions [15].
9

10 Previous size separation experiments with *C. aspersum* mucus found that component
11 proteins less than 30kDa in size did not appear to express antimicrobial activity [25].
12

13 Therefore, the identification of a 17.5 kDa protein ('protein 1') with possible anti-microbial
14 activity (Table 1, Table 2, Figure 3) which appears to be a sialic acid binding lectin was an
15 unexpected finding (Figure 6a). Some lectins have pathogen recognition receptor (PRR)
16 properties [30] and this could contribute to the anti-microbial activity. Gastropod lectins
17 have been known about for some time but to date none have been exploited for anti-
18 microbial treatments. Another unexpected finding was the 18.6 kDa protein ('protein 3')
19 within the 30-40 kDa mucus fraction (Table 2, Figure 3, Figure 4c). The sequence suggests
20 that it has a region consistent with the fibrinogen related domain (FreD). While fibrinogens
21 are well known and characterised in mammals for their role in coagulation, they are also
22 part of the invertebrate defence mechanism. FReDs work as part of the internal immune
23 system and they have agglutination and lectin-like binding properties [31]. However, some
24 FReDs with PRR and bacteriolytic properties – at least *in vitro* – are present in animals
25 including shrimp [32] and amphioxus [33]. Although the presence of the 18.6 kDa protein in
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

the anti-pseudomonal fraction of the mucus noted here could be co-incidental, this might equally play an important function in the observed anti-bacterial effect.

The initial SEC experiments suggested that the protein of around 50 kDa was present in large concentrations. It was therefore selected for sequencing by mass spectroscopy. The second SEC and testing of the fractions against *Ps. aeruginosa* indicated that this protein probably lacks antimicrobial activity. As Table 1 shows, the 50 kDa protein was present in fractions 3, 4 and 5, although only the first and last of these showed antibacterial activity.

Probing of the RNA transcriptome with the resulting peptides revealed a slightly larger protein of 64 kDa, 'protein 2' (Table 2, Figure 3). It remains unclear whether this is the protein identified as 50 kDa in the first SEC experiment. Protein 2 seems likely to be an extracellular matrix protein.

Strong anti-pseudomonal activity was observed with fraction 6 (Table 1) which contained the protein between 30 and 40 kDa. The work following this up has identified a 37.4 kDa protein, 'protein 4' (Table 2, Figure 3). It was found in three separate places in the transcriptome, which suggests it is important for the snail. Reports of proteins in this mass range within invertebrates are limited, but they function as part of the mammalian innate immune response and some have anti-microbial properties. For example, cathelicidin LL-37 has activity against *E. coli*, *Candida albicans* and *Staph. aureus* [34]. Another protein, CAP-37 [35] appears to target Gram negative bacteria and has a particularly strong effect on *Ps. aeruginosa*. The 37.4 kDa protein in *C. aspersum* mucus shares homology with a predicted collagen 6 (IV) protein in another species of snail, *Biomphalaria glabrata*, and a match to conserved domains of the von Willebrand factor A superfamily. Although it is an extracellular matrix protein, collagen 6(IV) from mammals has antibacterial properties and the significance of the vWFA domains in this effect was recently demonstrated [36].

1 Peptides containing the relevant domains are reported to have good activity against
2 selected bacteria, including *Ps.aeruginosa*. This may provide a partial explanation for the
3 antimicrobial properties of this novel protein, although BLAST results showed mapping to
4 only 55% of the *B. glabrata* protein.
5
6
7

8
9
10 The reason for the presence of a substance with targeted anti-pseudomonal activity in *C.*
11
12 *aspersum* mucus is not immediately clear. Although *Ps.aeruginosa* is a common soil
13
14 organism, to which terrestrial snails are continually exposed, there are many other potential
15
16 pathogens in the soil environment. *Ps. aeruginosa* is a known pathogen of insects, within
17
18 which it employs similar virulence factors to those in mammalian hosts [37]. *Pseudomonas*
19
20 spp. thrive in the environmental conditions provided by human mucus, especially in the
21
22 lungs of patients with cystic fibrosis [10, 38]. It is therefore possible that snail mucus has
23
24 similar constituents that can enhance the growth of these bacteria, which necessitates
25
26 specific protection. Also, a specific immunological interaction between this particular
27
28 mollusc and bacterium has been previously noted. Repeated injection with suspensions
29
30 containing high titres of *Ps. aeruginosa* have been shown to stimulate a measurable immune
31
32 response in *C. aspersum*, while preparations containing other microorganisms did not [39].
33
34
35
36
37
38
39
40

41 Thus, it appears that the anti-microbial proteins identified here could have a particular
42
43 function in contributing to protection of *C. aspersum* against *Ps.aeruginosa* infections. If this
44
45 could be ascertained, it may be possible to exploit it for development of treatment of
46
47 human infections with this bacterium. As the results presented here indicate there appears
48
49 to be promise for these proteins as treatment against *Ps.aeruginosa* strains implicated in
50
51 serious respiratory infections, but they could also be used to in preparations to target
52
53 infections in deep wounds . Therefore ,further characterisation of the form and function of
54
55 all these proteins would be beneficial. Production of purified versions of the proteins would
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

make them available in greater concentration than has been possible from crude mucus preparations. This would allow quantitative antimicrobial assays to be conducted as opposed to the qualitative results presented here. Re-investigation of the antimicrobial activity to confirm the specificity against *Ps. aeruginosa* could be conducted. Detailed observations of the site within the bacterial cell and mechanism of action of each of these proteins could be carried out.

Although four novel proteins have been identified here, the 37.4 kDa protein, to be named Asperrin, appears to be the most significant finding and it could be exploited to develop an antimicrobial substance for use in human medicine. Because *C. aspersum* is farmed commercially in several countries, it is already possible to source large numbers of snails at low cost. Therefore, unlike many naturally-derived pharmaceutical compounds, sourcing the raw material would not be a problem and the antimicrobial components might be separated out when the snails are processed for other purposes. This work represents an advance in biomedical science because it has identified a potential novel antimicrobial treatment against the clinical important pathogen *Ps. aeruginosa*.

Acknowledgements

We would like to thank Mrs C. Dedi and Ms R Berterelli and Mrs H Catty at Brighton University for technical assistance. We would also like to thank Prof Eshwar Mahenthiralingam of Cardiff University and Dr Brian Jones at Brighton University for supplying the clinical isolates of *Pseudomonas aeruginosa* and Dr Steve Lynham and Dr Malcolm Ward of King's College London, Dr Chris Taron of New England Biolabs and Dr Luca Lenzi of Liverpool University for providing scientific and technical expertise. We are grateful to Prof D. Timson and Dr L Bowler at Brighton University and Dr G. Weedall at Liverpool John Moores University for discussions of the results.

Funding

JAH was supported by a Research Development Grant from the Society for Applied Microbiology; SJP received support from a University of Brighton Rising Stars Award and an Output Enhancement Fund. AG received funding from the SCSTD voucher scheme at Liverpool John Moores University.

Disclosure statement

No conflict of interest was reported by the authors.

Summary table

What is known about this subject

- *Cornu aspersum* mucus has anti-microbial properties
- It is particularly effective against *Pseudomonas aeruginosa*
- The antimicrobial effect is attributable to one or more proteins between 30 and 100kDa in size

What this paper adds

- *Cornu aspersum* mucus contains several proteins with anti-microbial properties
- Three such proteins have been identified with masses of 17.5 kDa , 18.6 kDa and 37 kDa respectively, the most important of these is the 37kDa protein , Aspernin
- The mucus is effective against both type culture collection and clinical isolates of *Ps. aeruginosa*

References

- 1
2
3 [1] Holmes AH., Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of
4 antimicrobial resistance. *Lancet*, **2016**; 387:176-187.
5
6
7
8
9 [2] WHO World Health Organization. Critically Important Antimicrobials for Human
10 Medicine: ranking of antimicrobial agents for risk management of antimicrobial resistance
11 due to non-human use. 5th revision, **2016**; Geneva: World Health Organization. Retrieved
12 from <http://apps.who.int/iris/bitstream/10665/255027/1/9789241512220-eng.pdf?ua=1>
13
14
15
16
17
18
19
20 [3] Finley RL, Collignon P, Larsson .J. et al. The scourge of antibiotic resistance: the important
21 role of the environment. *Clin Infect Dis*. **2013**; 57:704-710.
22
23
24
25 [4] Buhl M, Peter S, Willmann M. Prevalence and risk factors associated with colonization
26 and infection of extensively drug-resistant *Pseudomonas aeruginosa*: a systematic review.
27 *Expert Rev Anti-infect Ther*. **2015**; 13:1159-1170.
28
29
30
31
32 [5] Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. *Nature* **2016**;
33 529: 336-343.
34
35
36
37
38 [6] Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nat*
39 *Med*. **2011**; 17:1217-20.
40
41
42
43 [7] Carson CF, Hammer KA, Riley TV. *Melaleuca alternifolia* (Tea Tree) Oil: A review of
44 antimicrobial and other medicinal properties. *Clin Microbiol Rev* **2006**; 19: 50-62.
45
46
47
48 [8] Juan, C, Peña, C, Oliver, A. Host and pathogen biomarkers for severe *Pseudomonas*
49 *aeruginosa* infections. *J Infect Dis* **2017**; 215(suppl 1): S44-S51.
50
51
52
53
54 [9] Tissot F, Blanc DS, Basset P, et al. New genotyping method discovers sustained
55 nosocomial *Pseudomonas aeruginosa* outbreak in an intensive care burn unit. *J Hosp Infect*
56
57
58
59
60 **2016**; 94: 2-7.
61
62
63
64
65

1
2
3 [10] Stefani, S., Campana, S., Cariani, L. et al. Relevance of multidrug-resistant *Pseudomonas*
4 *aeruginosa* infections in cystic fibrosis. Int J Med Micro **2017**; 307: 353-362.

5 [11] Vanneste, J.L. The scientific, economic, and social impacts of the New Zealand outbreak
6 of bacterial canker of kiwifruit (*Pseudomonas syringae* pv. *actinidiae*). Ann Rev Phytopathol
7
8 **2017** ; 55: 377-399.

9
10
11 [12] Streeter K, Katouli M. (2016) *Pseudomonas aeruginosa*: A review of their pathogenesis
12 and prevalence in clinical settings and the environment. Infection, Epidemiology and
13
14 Microbiology **2016**; 2:25-32.

15
16 [13] Bonnemain B. Helix and drugs: snails for western health care from antiquity to the
17 present. Evid Based Complementary Altern Med **2005**; 2:25-28

18
19 [14] Greistorfer S, Klepal W, Cyran N, et al. Snail mucus – glandular origin and composition
20 in *Helix pomatia*. Zoology **2017**; 122: 126-138.

21
22 [15] Pietrzyk, A, Bujacz, A, Mak P, et al. Structural studies of *Helix aspersa* agglutinin
23 complexed with GalNAc: A lectin that serves as a diagnostic tool. Int J Biol Macromol **2015**;
24
25 81:1059-1068.

26
27 [16] Mazzulla S, Anile D, De Sio S, et al. *In vivo* evaluations of emulsion o/w for a new topical
28 anti-aging formulation: short-term and long-term efficacy. J Cosmet Dermatol Sci Appl **2018**;
29
30 8: 110-125.

31
32 [17] Alogna A. New frontiers in snail mucus studies for cosmetic and pharmaceutical
33 preparations. Cosmetoscope **2017**; 23:1-6.

34
35 [18] Tsoutsos D, Kakagia D, Tamparopoulos K. The efficacy of *Helix aspersa* Müller extract in
36 the healing of partial thickness burns: A novel treatment for open burn management
37 protocols. J Dermatolog Treat **2009**; 20: 219-222

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[19] Ellijimi C, Hammouda M., Othman H, *et al.*, (2018) *Helix aspersa maxima* mucus exhibits antimelanogenic and antitumoral effects against melanoma cells. *Biomed Pharmacother* **2018**; 101: 871-880.

[20] Cilia G, Fratini F. Antimicrobial properties of terrestrial snail and slug mucus. *J. Complement Integr Med* **2018**; doi: 10.1515/jcim-2017-0168

[21] Iguchi SM, Takashi A, Matsumoto JJ. Antibacterial activity of snail mucus mucin. *Comp Biochem Physiol A Comp Physiol* **1982**; 72:571-574.

[22] Kubota Y, WatanabeY, Otsuka H, et al. Purification and characterization of an antibacterial factor from snail mucus. *Comp Biochem Physiol C Comp Pharamacol* **1985**; 82:345-348

[23] Otsuka-Fuchino H, WatanabeY, Hirakawa C. et al. Bactericidal action of a glycoprotein from the body surface of Giant African Land Snail. *Comp Biochem Physiol C Comp Pharamacol* **1992**; 101: 607-613.

[24] Zhong J, Wang,W, Yang X, et al. A novel cysteine-rich antimicrobial peptide from the mucus of the snail of *Achatina fulica*. *Peptides* **2013**; 39:1-5.

[25] Pitt SJ, Graham MA, Dedi CG, et al. Antimicrobial properties of mucus from the brown garden snail *Helix aspersa*. *Br J Biomed Sci* **2015**; 72: 174-181.

[26] Bortolotti D, Trapella C, Bernardi T. et al. Letter to the Editor: Antimicrobial properties of mucus from the brown garden snail *Helix aspersa*. *Br J Biomed Sci* **2016**; 73: 49-50.

[27] De Soyza A, Hall AJ, Mahenthalingam E, et al. Developing an international *Pseudomonas aeruginosa* reference panel. *Microbiologyopen*. **2013**; 2:1010-23.

[28] Gorbushin AM, Borisova EA. Lectin-like molecules in transcriptome of *Littorina littorea* hemocytes. *Dev Comp Immunol* **2015**; 48: 210-220.

[29] Gerdol M. Immune-related genes in gastropods and bivalves: a comparative overview.

Invert Surviv J **2017**; 14: 95-110.

[30] Trapella C, Rizzo R, Gallo S, et al. HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts. Sci Rep **2018**; 8: doi: 10.1038/s41598-018-35816-3

[31] Hanington PC, Zhang SM. The primary role of fibrinogen-related proteins in invertebrates is defense, not coagulation. J Innate Immun **2011**; 3:17-27.

[32] Wang XW, Wang JX. Diversity and multiple functions of lectins in shrimp immunity. Dev Comp Immunol **2013**; 39:27-38.

[33] Fan C, Zhang S, Li L. et al. Fibrinogen-related protein from amphioxus *Branchiostoma belcheri* is a multivalent pattern recognition receptor with a bacteriolytic activity. Mol Immunol **2008**; 45:3338-3346.

[34] Burton MF, Steel PG. The chemistry and biology of LL-37. Nat Prod Rep 2009; **26**: 1572-1584.

[35] Kasus-Jacobi A, Noor-Mohammadi S, Griffith GL. et al. A multifunctional peptide based on the neutrophil immune defense molecule, CAP37, has antibacterial and wound-healing properties. J Leukoc Biol **2015**; 9:341-350.

[36] Abdillahi, S.M., Maaß, T., Kasetty, G. et al. Collagen VI contains multiple host defense peptides with potent *in vivo* activity. J Immun **2018**; 201:1007-1020.

[37] Jander G, Rahme LG. Ausubel FM. Positive correlation between virulence of *Pseudomonas aeruginosa* mutants in mice and insects. J Bacteriol **2000**; 182:3843-3845.

[38] Langan KM, Kotsimbos T, Peleg AY. Managing *Pseudomonas aeruginosa* respiratory infections in cystic fibrosis. Curr Opin Infect Dis **2015**; 28: 547-556.

[39] Bayne CJ. Molluscan immunity: induction of elevated immunity in the land snail (*Helix*)
by injections of bacteria (*Pseudomonas aeruginosa*). Dev Comp Immunol **1980**; 4:43-54.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. Antimicrobial disc diffusion plate assays using *Cornu aspersum* mucus demonstrating inhibition of *Pseudomonas aeruginosa* NCIMB 10548. Mucus preparations were tested in triplicate. P = phosphate buffered saline control.



Figure 2a: SDS PAGE analysis of the protein profile of two of pooled fractions (A and B) from the initial Superdex 16/60 run, showing strongly staining bands at 50 kDa and 17 kDa in Fraction A.

Molecular weight ladder is on the left hand side




Figure 2b : Trace showing of fractions collected after running the mucus through a Superdex 75 26/60 column




Figure 2c: SDS-PAGE analysis of proteins in peaks 2-6 from Figure 2b. Molecular weight ladder is on the right hand side




Figure 3: Protein sequences 1-4 peptide sequences are highlighted

Figure 3: Protein sequences 1-4 peptide sequences are highlighted

Protein 1 MSLAIFVGVAIYAAAAAQEFI **GNVAFTAATEDTVAEGR**LVQYPVFTNHGSGYNSNTGIFIATKGGLYVFHGHQPTAGNDFSLTYHNDNPIITASGRQQGDNVGTGSNSVTLRLKKNDRVSVKADIRSSLRGSSDSVFTFSGYLIGLLTSEL

Protein 2 AVVCCSYMLREKMVALHLLLMALS AVAVIDGHYGRGGGYRGGHGGGYPGGRPHGGGRYGGGYGGRPYGGHHGRPHYGFRGYGGAGGYVYTHGAGGGFIGAVDPYGWCQQTNDHGHSTGKVEKCPAIDIIVLLDTSSMSRQEFELERNFAALLTEHFNVASGGVR **FGAV**
TFSDRVYESFNLASYSNEAVKTAFRNTAYLAGGK**TYLALDY**IRVNRLFSTSRGARDKSSKIVVLTGYSDSRSATKYAADALKNTGVKVISVGIGGSLGEELRNMASDGLVFSADTFQSLTRIEQRVAASICSIPESGYVPPTEDEGKGDTKCQEGFKPNRNPSTCIDIDECQTNNPCQQT
CVNLPGSVRCTCKADFVINPKDITKCNALRQCND**LVDIVFLVDESGSIG**ADNFKLQQTFAKLQHFVNGSNGARFAGVQFATQVKKLFDLNKYSSSKDISSALLGTPYEGGNTNHLGLNYIADNKLFTASGGRSNAPDVVIVVTDGESARPEQTKQAADRLKQQGATVVS VGVGDQVK
TSELIDIAS SKDDVFVVSDFDLDYIEENLTERICPSTRS

Protein 3 IERRVSDDVDFKRTWADYKKGFSGVSDSSYFIGLEPLHLLSDLGFNELRIDFKVDDKTYAHYDFK **VGGEDAYK**LNVKDYSGDAGDSFSYYDGAVFSTSDSDHDADAKNCADISGGGWYKDCLAGLNGVYGHVTPDGIYWKTLNLKKPIQYLEMKVRNPNYEQGYN

Protein 4 MNRRFICGVLLVVSVTTISQGERFVFSATPITISPGVTPELTVR **CGL**ED**DGNS****GVS**RVNSIIIRTVDGVSQKEVARIAYSQAAGGFSTERSVT**GD**LSNKAG**YLQITW****PS**IHGLAGQYNCDAAL**ATVGD**VTFKSSMRVISTGFRQCYELVDIVFLVDESSIGAVNFKLLQTF**LA****NT**QHFK
VGSNGARFAGVQFATQVKKLFDLNKYSSSKDISSALLGTPYQGQSTYHLGLNYIADNKLFSASGGRSNAPDVVIVVTDGESTMPEQTKQAADRLKQQGATVVS VGVGGQFKTSELFDIASSKDAV FVVSDFNLLYIENNLARVCPSTRS

Table 1: Characteristics of each peak from Figure 2b in terms of activity against *Ps.*

aeruginosa

NCIMB 10548 and sizes of the proteins in each peak as determined by SDS-PAGE

Peak	Mean zone of inhibition, mm	Protein sizes, kDa
2	0	250, 116, 72
3	14	56, 50, 17, 15, 12
4	0	60, 50, 23, 20, 13
5	12	50, 24, 20, 17, 14
6	14.5	39, 12, 10, 5

Table 2: Peptides obtained from the 17kDa, 50kDa and 30-40kDa proteins the matches in the transcriptome

Table 2: Peptides obtained from the 17kDa, 50kDa and 30-40kDa proteins the matches in the transcriptome

Peptide	Putative protein from Mass Spectrometry (MS)/ HPLC- chromatogram (HPLC)	Sequence	Match to transcriptome database
1	17 kDa (MS)	LGNVAFTAAFTEDTSVAEGR	Protein 1
2	17 kDa (MS)	ANLLSGLLKTVVGLVGGGLVKGDEVYVK	No match
3	50 kDa (MS)	GTYLALDYL	Protein 2
4	50 kDa (MS)	WWLVnLLmLVnESGSLGPPK	Protein 2
5	50 kDa (MS)	WWLVDLLFLVDESGSLGPPK	Protein 2
6	50 kDa (MS)	FGAVTFSDR	Protein 2
7	50 kDa (MS)	VFDWGVTTLNK	No match
8	50 kDa (MS)	LVLVTDGNSDSFLTNAANLQK	No match
9	30-40 kDa (HPLC)	VVCGTWWDTLMYR	No match
10	30-40 kDa (HPLC)	QYLQVTWSSPR	No match
11	30-40 kDa (HPLC)	VGGEDAYYK	Protein 3
12	30-40 kDa (HPLC)	TNLGGLSSVHNEEGVVSCR	Protein 4
13	30-40 kDa (HPLC)	ATVGDLVKF	Protein 4
14	30-40 kDa (HPLC)	KLAKVF	Protein 4
15	30-40 kDa	ATAGDLVKF	Protein 4
16	30-40 kDa	TAGDLVKF	Protein 4
17	30-40 kDa	CGLEDEGLTGVSRR	Protein 4
18	30-40 kDa	DVANTKNLRY	Protein 4